New strategy aims to make targeted therapy work longer for colorectal cancer patients
NCT ID NCT04587128
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether giving anti-EGFR drugs (panitumumab or cetuximab) early in treatment can help patients with left-sided metastatic colorectal cancer respond again to these drugs later. About 34 participants will receive alternating cycles of targeted therapy and chemotherapy over up to 5 years. The goal is to see if this approach improves disease control and delays progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Panitumumab, Cetuximab, Irinotecan, FOLFIRI, Bevacizumab
What this could lead to
If successful, this strategy could help some patients with metastatic colorectal cancer get more benefit from anti-EGFR therapies by using them earlier in treatment.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The approach may not improve disease control or survival, and side effects from the drugs can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States